M-A: Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients.
Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis – Reviews in Medical Virology
The post M-A: Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients. appeared first on Links Medicus.
-
Taille de police
Réduire la taille de la police
Augmenter la taille de police
About Author
Dernier de Zouhair Souissi
- Non-inferiority RCT: Reduced-Dose vs Full-Dose Direct Oral Anticoagulants for Extended VTE Treatment
- Systematic Review: Shorter Antibiotic Courses Often Prove Non-Inferior for Common Bacterial Infections
- Network Meta-analysis: Oseltamivir Fails to Improve Key Outcomes in Nonsevere Influenza
- Multidrug-resistant Gram-negative bacterial infections: Key Updates and Practical Strategies
- Introducing Our Free WhatsApp Channels for Daily Internal Medicine Articles!